You can't always get what you want, but if you try sometimes, you get want you need. Rolling Stones
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All I hear is music on the CC site. Anyone talking?
That means the share price is now $4.79 (another 52 week high). Plus the NFL NEWS was just released.
IMO the are the shorts are begrudgingly giving up, not a short squeeze as we know it, the shorts are slowly but surely selling. I also believe a large number of shorts have switched to being longs. Plus, those that previously sold after a run up like we are now experiencing, are holding on since they like me believe the run is no way over. $8-10 is not out of question by the end of the year. Very likely $6-7 right after earnings (8/5 pm).
DeGen
Ps: testing testing testing!!!
Testing testing testing!!!
I must chirp in on you comments on Cramer. He has, singled handed, been the educational tool for the many non professional investors out there. He gives the straight unbiased opinion of stocks from a person that probably is the most knowledgeable stock expert around. All for free if you just spend the time to listen to him on TV. I personally have over 21 years of education and have had many professors, but Cramer by far is my most respected “educator”.
DeGen
Double exposure on CNBC today. First a 3+ minute with Jon Cohen. Then a Call in question for Cramer where he says it might go to $5 (if they get the nfl contract). Cramer likes the testing lab Bioreference.
DeGen
on 6/24 (12 trading days ago) OPK closed at $2.56
today 7/10 OPK closed at $4
Did anybody miss that <50% jump in 12 days?
Was the short squeeze the cause of this increase?
Was the increased income from the testing?
Was the increase in the drugs sales (Rayadyne)
Was the hope for the deveolpment of growth hormone drug?
Was the increasing awareness of 4KScore test?
Was the testing for a Covid19 cure/vaccine?
MAYBE ALL OF THE ABOVE?
Maybe finally these facts are now being "learned" by more and more of the investment experts.
DeGen
ps; didn't mention the possible buy out by Pfizer as its a long shot
Any updates on the number of shorts currently?
Last data is from June 15. I am sure some were recently squeezed out since then.
does anyone know how locate a more current account of the short interest? June 15 is ages ago.
at 1:15 high of day $4.16 (+32)
Did I hear Dr. Frost singing “who wears short shorts”?
DeGen
Ps: that song is for you you Howie.
Those that thought the share price would be pennies up or down at the close were DEAD WRONG! Those that are always Debbie Downers can not force the price down, only hope it will go down. OPKO has too many good things going for the price to continue its climb to $4-5 soon enough. Then up to double figures as the shorts continue to get squeezed out. Sorry HD.
DeGen
Repost with earning date.
It should be a slow but sure climb to $4-$5 as we approach the quarterly earnings report on Aug 5. Maybe some bumps along the way, but those will be buying opportunities. There should be a real pop on the earnings release day. I expect a pullback after any big pop, but I expect an overall uptrend with all the good things Opko has going for it.
DeGen.
It should be a slow but sure climb to $4-$5 as we approach the quarterly earnings report on Aug 5. Maybe some bumps along the way, but those will be buying opportunities. There should be a real pop on the earnings release day. I expect a pullback after any big pop, but I expect an overall uptrend with all the good things Opko has going for it.
DeGen.
The virus has affected companies in different ways:
Some companies completely destroyed
Some companies hurt but will recover
Some companies not affected at all
And some companies that have greatly benefitted by the virus
Which category does OPKO fall into?
This should continue for months if not years to come.
Testing testing testing.
$3.09 this AM
TESTING TESTING TESTING
Did someone else say, testing, testing, testing.
Reminds me of a company that has a testing lab. Is it Opko?
Testing Testing Testing
What company benefits from that?
Tonight on 60 Minutes there was a segment on testing companies (from China) that were selling bogus test kits. The USgovt allowed this to happen based on the urgency of the situation. Now that this has become a problem, more agencies will probably only buy from reliable sources like our test kits. This should help sales, as though our sales really help. I assume we are selling all we can produce right now. In any case this is good news for established companies like OPKO. Hope to see a gap up tomorrow AM.
$7.55 at 11am
20% pop so far today. Does anyone know why?
Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the detection of antibodies that identify if a person has been infected with the novel coronavirus (COVID-19). Antibody testing can be an important next step in opening the economy to tell people if they have been previously infected. This is the third COVID-19 antibody test introduced by the Company. The other two, which are finger-prick rapid tests, are actively being sold outside of the US and have been well received. The Company also intends to obtain a CE mark to market and sell this ELISA laboratory test outside the US.
Biomerica performed testing both internally and at two external labs located in California. The data from this testing that was submitted to the FDA under the EUA application showed 100 percent specificity and zero percent cross reactivity with many common disease states. This test, which uses the ELISA microplate format, can be run on existing open system equipment found in most hospitals and clinical laboratories in the US and outside the US and uses a modified, trimeric spike protein from the SARS-CoV-2 virus. This spike protein is known to be the target of neutralizing antibodies, which can help prevent the virus from entering the cells.1 Persons who are no longer infectious and have tested positive for the antibodies, can possibly be cleared to return to work as they may have a lower likelihood of reinfection and/or spreading the virus. Antibody tests will also help in better understanding the virus including how long antibodies stay in the body and if they help in immunity as well as how many people have been infected in the population as a whole. Further, this type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals.
This ELISA laboratory test was developed by Biomerica and will be manufactured exclusively at Biomerica’s manufacturing facility located in Irvine, California, using existing high-throughput, automated equipment. Biomerica has extensive experience manufacturing similar serology ELISA tests for other diseases.
"We are working to provide significant, high specificity and meaningful diagnostic solutions for the novel Coronavirus," said Zack Irani-Cohen, CEO and Chairmen of Biomerica. "Our ELISA test will be unique in the market place by simplifying the blood sample collection process in a proprietary way. We have been working with the FDA, who has been very responsive, and we’re looking forward to a quick review for this submission. I’m very proud of our team members who are working around the clock to develop, validate and attain regulatory clearance on these covid-19 diagnostic solutions that benefit patients, healthcare workers and society”.
About Serology Tests
Serology tests look for the presence of antibodies, which are specific proteins made in response to infections. The antibodies detected by serology tests indicate that a person has had an immune response to the novel Corona Virus (SARS CoV-2), whether symptoms developed from infection or the infection was asymptomatic. Antibody test results are important in detecting infections with few or no symptoms.2
1. medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20047365. Accessed 15Jun20
2. Emerging Microbes & Infections 2020, VOL. 9 Molecular and serological investigation of 2019-nCoV infected patients.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on Gastrointestinal and inflammatory Diseases where the Company has multiple diagnostic and therapeutic products in development.
About InFoods®
The Biomerica InFoods® IBS product is designed to allow physicians to identify patient specific foods (e.g. eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company’s COVID-19 test, FDA clearance, EUA clearance, the rapidity of testing results, uniqueness of a product, pricing of the Company’s test kits, demand for international orders, availability of the Company’s COVID-19 test kits, and patent protection on the test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company’s COVID-19 test; regulatory approvals necessary prior to commercialization of the Company’s COVID-19 test; availability of the Company’s COVID-19 test kits; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our COVID-19 test; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company’s ability to obtain patent protection on any aspects of its rapid test technology. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
CONTACT INFORMATION
Company Spokesperson
949-645-2111
www.biomerica.com
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19
At least this pullback by OP K is based on the entire market turn down not just the company. This market pullback was long overdue, so it’s no surprise. Our share price should recover very soon as we still have so many things going for it and any one of them will propel the share price higher.
There is no question in my mind that a good part of the meteoritic rise is a short squeeze and its about time. OPKO is big time now and anyone who shorts this company has not done their DD. OPKO has so many irons in the fire and each one can and will propel the share price higher and higher.
DeGen
PS Hitting $2.90 at 9am premarket
In the past, after a big quick run up in the share price, there has normally been a pull back. However, IMO, this time will be different. The shorts are being squeezed. There is a content full of good news (although OKPO PR department is terrible) and so many things are in the hopper. If the next Q shows a greatly reduced loss or at best a PROFIT, the share price should really take off. Soon the institutions will take notice and there will be buying in big chucks. So much upside, so little downside. Shorts being squeezed in every direction. This time the usual sellers that jump ship after a big spike will not only stay aboard but will be buying more. Watch out!!!
DeGen
Hit $3.00 this year? I am sure you meant hit $3 this MONTH!
Item 7.01 Regulation FD Disclosures.
On June 1, 2020, Biomerica, Inc. (“Biomerica”) issued a press release announcing that it had signed agreements with Mayo Clinic to join its clinical trial for its InFoods product. It also announced that it had received a patent in Japan pertaining to its Infoods product. A copy of Biomerica’s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.
The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Plus $0.02 after hours up to $2.30.
I don’t understand this low stock price as there is so many plusses with this company.
With the possibility of a profitable next Q, this should be at least $3.
Bounce will occur when they get US approval
As I watch the business news, I can’t help feeling good about owning OPK every time anyone mentions, TESTING, TESTING, TESTING. I know one company that will benefit.
I believe that OPK will be profitable in in Q2 which will bring in the institutional investors and take this stock to at least to $5.
DeGen
Just maybe some of the multi millions of dollars that is going to be spent world wide on testing will find its way to BMRA. Especially now with BMRA receiving the CE mark.
On May 5, 2020, Biomerica received a CE mark and launched a new high-volume production version of its COVID-19 IgG/IgM Rapid Test (the “COVID-19 Test”) that utilizes a proprietary card system that eliminates most plastic. The COVID-19 Test is a serology, finger prick blood test designed to detect antibodies in a person to indicate if that person has had an immune response to the novel Corona Virus (SARS CoV-2). In addition, Biomerica expanded its provisional patent applications to include new technology that is being validated to simplify blood sample collection for its high throughput ELISA test.
From the Form 8K issued today:
On May 7, 2020, Biomerica, Inc. (“Biomerica”) issued a press release announcing the receipt of a CE mark for a new high-volume version of a ten-minute test for COVID-19 exposure and the expansion of its international distribution. A copy of Biomerica’s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.
Maybe Frost is prohibited from buying just before the the quarterly report?
what will America choose?
A quick test by Abbott Labs (a renown Amercian Drug Co.)
or
A quick test by BioMerica (a 14 yr start up Drug co with a market cap of 69M).
Which test is more reliable?
Which test has FDA approval?
Who is capable of supplying millions and millions of tests the quickest and most reliable?
BMRA may get some business, but not likely.
BMRA share price will likely tank over the next few weeks, so get out while you can?
DeGen
I just sent this "correction" into CNBC news site. I would hope that at least ten others here cut and paste what I wrote and send it in to CNBC as well. Of course if you use you own words that would be better, but the more that write in, the more likely BioReference Lab will show up on the list.
When CNBC reports the Kit Providers (which is done several times a day), it lists:
Thermo Fisher
Roche Holdings
Holigic
Lab Corp.
Missing from this list is BioReference Lab (owned by OPKO) which has been providing tests at drive through facilities for New York City, Detroit and all of New Jersey. BioReference Lab Corp has been providing tens of thousands of these COVID-19 tests each day for some time now and should be on this list. Please contact Dr. Jon Cohen, Exec Chairman, BioReference Lab (800-229-5227) to confirm this information.
Can you please add BioReference Lab that is vital to providing test kits to your list when you put it on the screen next time.
xray, this stock is VERY risky, 5 days ago at $2, then $6, then $9, then hit $23.38, then back to $16 yesterday, and now today in the $7s. That's over 5 f'en days! Be careful!
This COVID test is not available or approved in the US for good a reason. My guess that's is all hype (or BS) by the pink sheet pumpers, but what do I know.
I do know others test labs like BioReference Labs who have contracts with NY and NJ to do thousands of tests via drive throughs. These $50 per head tests will be bringing in tons of revenue. BioReference Lab is owned by OPKO a NYSE company.
Who do you trust?
xray, this stock is VERY risky, 5 days ago at $2, then $6, then $9, then hit $23.38, then back to $16 yesterday, and now today in the $7s. That's over 5 f'en days! Be careful!
This COVID test is not available or approved in the US for good a reason. My guess that's is all hype (or BS) by the pink sheet pumpers, but what do I know.
I do know others test labs like BioReference Labs who have contracts with NY and NJ to do thousands of tests via drive throughs. These $50 per head tests will be bringing in tons of revenue. BioReference Lab is owned by OPKO a NYSE company.
Who do you trust?
I am down a lot of money too, but after listening to the CC, I am confident Biomedical Lab will have a unbelievable impact on OPKO's bottom line real soon. The number of tests will just keep increasing over the next few weeks as the demand is insatiable.
As far as the stock price goes, it makes no financial sense to be going down now with income increasing by the day for the next several months. My guess is that there will be an unbelievable up surprise in income resulting in a stock price spurt way up.
Again, it makes no sense for the share price to be going down, unless the shorts are somehow manipulating it.
DeGen
Ps: Everyone should listen to the CC and then will become a believer!
Just saw CEO Stanford Health Care on CNBS talking about drive through test in the SF Bay Area.
Why cant Cohen of BioReference Lab get on TV as well?
OPKO, how about a PR as well?